DUBLIN – The cash spigot is still turned on, as two more European firms disclosed series A rounds on Oct. 13. Chord Therapeutics SA took in €16 million (US$18.8 million) to repurpose cladribine for rare autoimmune disorders. Rappta Therapeutics Oy raised €9 million to take forward a novel concept in cancer, focused on developing small-molecule activators of protein phosphatase 2A (PP2A).